| |
April 3-4, 2023 | San Diego, CA The only west coast event exclusively for life science communicators to share best practices, benchmarks, and tools, as well as network with peers. Early Bird Rate Ends January 27th.
|
|
Today's Big NewsJan 25, 2023 |
| By Angus Liu Moderna and BioNTech recently reported positive early clinical data for their mRNA cancer vaccine in partnership with PD-1/L1 inhibitors. But as over a decade of research has failed to transpire into approved therapies, several biopharma executives remain on the fence about the future of these vaccines future, while others believe the field is getting closer to finding its sweet spot. |
|
|
|
By Kevin Dunleavy In December, Sens. Elizabeth Warren, D-Massachusetts, and Peter Welch, D-Vermont, sent a letter to Pfizer admonishing the company for a proposed increase in the price of its COVID-19 vaccine for up to $130. Six weeks later, they've turned their attention to the world’s other leading producer of COVID vaccines, Moderna, which also has said it might charge up to $130 per dose when the United States stops providing shots for free and goes to a commercial model. |
By Andrea Park More than two years after submitting it for FDA review, Tidepool has scored the agency’s clearance for a smartphone app that allows people with Type 1 diabetes to build their own closed-loop “artificial pancreas” system. |
By Robert King New FCC guidance allows states and managed care plans to text Medicaid beneficiaries on potential changes to their coverage. |
|
Thursday, February 16, 2023 | 11am ET / 8am PT Join this session as a panel of experts discusses the realized benefits of using AI and communication tools to redefine the care pathway to detect stroke and streamline the patient journey to direct more patients for cardiology follow-up. Register now.
|
|
By Max Bayer Entering his third year on the job, Roivant CEO Matt Gline is pushing back against the company's reputation as a discard company fishing for projects to rebuild. |
By Fraiser Kansteiner On April 3, George Scangos, Ph.D., who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. |
By Andrea Park Abbott experienced a steep drop in COVID test sales in the final months of 2022, when it took in around $1.1 billion in sales from the segment, less than half of the $2.3 billion it clocked for the fourth quarter the previous year. |
By Kevin Dunleavy Abzena has laid off 66 employees in San Diego, according to a Worker Adjustment and Retraining Notification (WARN) posted by the state. The move comes amid an apparent period of transition for the company, which hired a new CEO in early January. Then last week, Abzena sold its new biologics drug substance facility in North Carolina to Pfizer. |
By Paige Minemyer Elevance Health's profit for the fourth quarter of 2022 declined year-over-year, but still beat the Street, according to the company's latest earnings report released Wednesday. |
By Nick Paul Taylor Vertex and CRISPR Therapeutics have taken a small step toward a landmark approval, securing European Medicines Agency (EMA) validation of the approval application for their CRISPR-Cas9 candidate. |
By Conor Hale Intuitive Surgical saw the number of its robotic procedures continue to bounce back compared to 2021 during some of the high points of the pandemic. |
By Sharon Klahr Coey Bristol Myers Squibb is going big on its DTC push for its two immunotherapies—the newer Opdualag and two drugs in one combo of Opdivo (nivolumab) and Yervoy. |
By Dave Muoio Loosened DEA requirements included in December's omnibus bill increases the number of providers who can prescribe buprenorphine for opioid use disorder from 130,000 to 1.8 million, government officials said Tuesday. |
By Eric Sagonowsky As the biopharma industry moves beyond its groundbreaking pandemic response, we're looking for leaders with ideas that'll shape the future of the industry. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we take you inside Fierce's JPM Week event. Listen in on snippets from a lively panel discussion on how companies will navigate the drug pricing policies the Biden administration rolled out just last year. And hear from Christine Roth, head of Bayer's oncology strategic business unit, about the company's plans to become a strong competitor in cancer. |
|
|---|
|
|
|
Tuesday, February 7, 2023 | 11am ET / 8am PT This session will focus upon understanding your knowns and unknowns, best practices for mitigating risk and addressing the specific drug supply challenges commonly associated with adaptive, decentralized, platform and other complex trial designs. Register now.
|
|
| WhitepaperRCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| WhitepaperThis paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
